Analyzing BioForce Nanosciences (OTCMKTS:BFNH) & Revvity (NYSE:RVTY)

BioForce Nanosciences (OTCMKTS:BFNH) and Revvity (NYSE:RVTY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, analyst recommendations, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares BioForce Nanosciences and Revvity’s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioForce Nanosciences	N/A	N/A	-$490,000.00	N/A	N/A
Revvity	$2.80 billion	3.89	$569.18 million	$5.95	14.81

Revvity has higher revenue and earnings than BioForce Nanosciences.

Analyst Recommendations

This is a breakdown of current ratings and target prices for BioForce Nanosciences and Revvity, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioForce Nanosciences	0	0	0	0	N/A
Revvity	0	2	5	0	2.71

Revvity has a consensus target price of $118.71, indicating a potential upside of 34.72%. Given Revvity’s higher possible upside, analysts clearly believe Revvity is more favorable than BioForce Nanosciences.

Volatility & Risk

BioForce Nanosciences has a beta of -1.34, meaning that its share price is 234% less volatile than the S&P 500. Comparatively, Revvity has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500.

Profitability

This table compares BioForce Nanosciences and Revvity’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioForce Nanosciences	N/A	N/A	-68,525.80%
Revvity	26.90%	8.30%	4.56%

Institutional and Insider Ownership

82.6% of Revvity shares are held by institutional investors. 39.5% of BioForce Nanosciences shares are held by insiders. Comparatively, 0.5% of Revvity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Revvity beats BioForce Nanosciences on 9 of the 10 factors compared between the two stocks.

About BioForce Nanosciences

BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. The company offers private label products with distributors and manufacturing providers. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online under the BioForce Eclipse brand, as well as through social media and telemarketing. BioForce Nanosciences Holdings, Inc. was incorporated in 1999 and is based in Virginia Beach, Virginia.

About Revvity

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.